Scholarlink

<p>By inducing growth of the intestinal epithelium, the drug teduglutide, used for the treatment of short bowel syndrome-associated intestinal failure, could feasibly promote growth of pre-existing colonic neoplasms and incite the development of new ones. A baseline screen for colonic lesions and a 1-year follow-up have therefore been recommended, although an ongoing global prospective registry has, to date, shown no promotion of colonic neoplasms. Most recently, there have been reports of patients developing upper intestinal polyps while on the drug, including ones with malignant potential. To ensure patient safety, the Committee overseeing the global registry therefore recommends that monitoring strategies be updated to include screening for small intestinal lesions as well.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Add-on to current guidelines for monitoring of SBS patients treated with teduglutide

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月6日

查看全文
  • Francisca Joly,
  • Johane P. Allard,
  • Gabriel E. Gondolesi,
  • Palle Bekker Jeppesen,
  • Martina Kohl-Sobania,
  • Ulrich-Frank Pape,
  • Loris Pironi,
  • Lauren K. Schwartz,
  • Joel Mason

摘要

By inducing growth of the intestinal epithelium, the drug teduglutide, used for the treatment of short bowel syndrome-associated intestinal failure, could feasibly promote growth of pre-existing colonic neoplasms and incite the development of new ones. A baseline screen for colonic lesions and a 1-year follow-up have therefore been recommended, although an ongoing global prospective registry has, to date, shown no promotion of colonic neoplasms. Most recently, there have been reports of patients developing upper intestinal polyps while on the drug, including ones with malignant potential. To ensure patient safety, the Committee overseeing the global registry therefore recommends that monitoring strategies be updated to include screening for small intestinal lesions as well.